News|Articles|November 17, 2026

Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC

Author(s)OncLive Staff
Fact checked by: Caroline Seymour
Listen
0:00 / 0:00

Key Takeaways

  • Quantitative TROP2 NMR (QCS) enriched Dato-DXd benefit in TROPION-Lung01, whereas NMR failed to stratify outcomes in EGFR-mutant cohorts, complicating biomarker strategy.
  • Sacituzumab tirumotecan improved PFS and OS versus platinum doublet post–EGFR TKI and showed strong frontline PFS with pembrolizumab in PD-L1–negative disease, with manageable ILD.
SHOW MORE

Antibody-drug conjugate (ADC) development in non–small cell lung cancer (NSCLC) has converged on a handful of targets and one dominant payload class, and the next gains may depend more on payload, linker, and patient selection than on the target itself, according to Alissa Cooper, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts.1 Speaking during a presentation at the 44th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow, Cooper reviewed established targets, emerging targets, and new payload designs, the last of which she called "our area of greatest need."1

Key Takeaways on Novel ADC Constructs and Targets in NSCLC

  • Target expression measured by conventional immunohistochemistry has not reliably predicted benefit from antibody-drug conjugates in NSCLC, and better biomarkers are needed to identify which patients will respond.
  • The efficacy and tolerability of an antibody-drug conjugate depend on its payload, linker, and therapeutic window, not only on the antigen it targets.
  • Because most current agents share a topoisomerase I inhibitor payload, novel payload mechanisms and dosing strategies beyond the maximum tolerated dose will be key to effective sequencing.

Can TROP2 expression predict who benefits?

About half of recent ADC trials have required biomarker selection by immunohistochemistry (IHC) or genomic testing, which Cooper said oversimplifies patient selection. "While we have biomarker-selected patient selection trials, I do think that we need to figure out more deeply what are the patients that are going to benefit," she said.1

One attempt to look deeper is the TROP2 normalized membrane ratio (NMR), a computational pathology score assessed by quantitative continuous scoring (QCS).2 In the biomarker-evaluable population of the phase 3 TROPION-Lung01 trial (NCT04656652), patients with QCS-NMR–positive tumors who received datopotamab deruxtecan (Dato-DXd; Datroway) had an objective response rate (ORR) of 32.7% vs 10.3% with docetaxel and a median progression-free survival (PFS) of 6.9 vs 4.1 months (HR, 0.57; 95% CI, 0.41-0.79). In NMR-negative patients, the curves overlapped (HR, 1.16; 95% CI, 0.79-1.70).2

That signal did not hold in EGFR-mutated disease. Among 68 patients with EGFR-mutated nonsquamous NSCLC from TROPION-Lung01 and the phase 2 TROPION-Lung05 trial (NCT04484142), median PFS with Dato-DXd was 5.8 months in NMR-positive and 5.7 months in NMR-negative patients (HR, 0.95; 95% CI, 0.53-1.72).3 "[This] calls into question, what is the biomarker for these patients?" Cooper said. "Is it the EGFR mutation itself?"1

How are next-generation TROP2-directed ADCs performing?

Sacituzumab tirumotecan (sac-TMT) now has randomized data against a demanding comparator. In the phase 3 OptiTROP-Lung04 trial (NCT05870319), which enrolled patients with EGFR-mutated NSCLC after EGFR TKI progression, sac-TMT improved PFS vs platinum doublet chemotherapy,4 and the final analysis showed a median overall survival (OS) of 25.9 months vs 17.4 months (HR, 0.69; 95% CI, 0.54-0.89).5 No patient discontinued sac-TMT because of treatment-related adverse events, and interstitial lung disease (ILD)/pneumonitis occurred in 1 patient.5 "I don't think we've seen this randomized control in this space before, especially with such a strong control arm as platinum doublet," Cooper said.1

She found the frontline data even more striking. In the phase 3 OptiTROP-Lung06 trial (NCT06711900), sac-TMT plus pembrolizumab (Keytruda) produced a median PFS by blinded independent central review of 15.0 months vs 5.7 months with chemotherapy plus pembrolizumab in patients with PD-L1–negative nonsquamous NSCLC (HR, 0.49; 95% CI, 0.36-0.65; P < .0001). Grade 3 or higher adverse events were less frequent with sac-TMT (47.6% vs 60.6%).6,13 "This was very, very encouraging data, in my opinion," she said.1

What do next-generation HER2- and MET-directed ADCs add?

Trastuzumab rezetecan (SHR-A1811), which pairs a second-generation topoisomerase I inhibitor payload with a stability-engineered linker, produced an ORR of 73% with an ILD rate of 5% in patients with previously treated HER2-mutant NSCLC in the phase 2 portion of the phase 1/2 HORIZON-Lung trial (NCT04818333) in China.7

For MET, telisotuzumab adizutecan (Temab-A) yielded an ORR of 69% and a median PFS of 11.0 months among patients with MET-amplified NSCLC (n = 29) in the first-in-human phase 1 M21-404 trial (NCT05029882), with an adjudicated ILD rate of 4% and no treatment-related deaths.8 "This is the trend we're starting to see a little bit more of: this wider therapeutic window in these next-generation agents, a little bit more efficacy and a little bit less toxicity," Cooper said.1

In the trial's EGFR-mutated cohort (n = 41), Temab-A produced an ORR of 63% and a median OS of 16.2 months; Cooper noted that responses appeared similar regardless of c-Met protein level.1,9 "It's not just the target that's important," she said. "It's the payload delivery. It's the therapeutic window, and all of that seems to matter a bit more."1

What has integrin beta-6 taught the field?

Integrin beta-6 (IB6), an epithelial target overexpressed in lung and head and neck cancers, offered a cautionary example. In the phase 1 SGNB6A-001 trial (NCT04389632), the monomethyl auristatin E–based ADC sigvotatug vedotin produced an ORR of 19% across 117 patients with NSCLC and 29% among those with nonsquamous, taxane-naive disease.10

In the phase 3 SigVie-002 trial (NCT06012435), sigvotatug vedotin did not improve OS vs docetaxel (11.9 vs 11.5 months; HR, 0.929; 95% CI, 0.767-1.126), and peripheral sensory neuropathy (27% vs 19%) and nausea (29% vs 19%) were more common with the ADC.11 An exploratory analysis found no clear relationship between IB6 expression and activity, reinforcing her view that "IHC expression is not something we can hang our hat on here for making clinical decisions."1

Cooper still considers IB6 promising; PF-08046876, an IB6-directed ADC with a topoisomerase I inhibitor payload, is in a phase 1 trial (NCT07090499). "I've put quite a few patients on this trial at my institution," she said. "[It] does seem to be working pretty well, so we'll see how that shakes out."1

Where does the EGFR x HER3 bispecific ADC fit?

Cooper called izalontamab brengitecan (iza-bren) "really exciting." In the phase 3 PANKU-Lung01 trial (NCT06382116), conducted in China in patients with EGFR-mutated nonsquamous NSCLC after progression on a third-generation EGFR TKI, iza-bren achieved a median PFS of 11.1 months vs 5.7 months with platinum-based chemotherapy (HR, 0.40; 95% CI, 0.31-0.51; P < .0001); median OS was not reached vs 19.4 months.12,14 She noted that neither arm continued the TKI, as is common in the United States, and that the data need to be recapitulated outside China; intracranial activity and combination with osimertinib (Tagrisso) remain to be defined.1

What unmet needs remain in ADC design?

Cooper argued that new payloads matter more than new targets, because most current agents share a topoisomerase I inhibitor warhead. "We're learning more and more that sequencing the same type of payload delivery is not going to be effective for people," she said.1 Candidates include targeted protein degraders, immune-stimulating antibody conjugates, transcription-targeting agents, and anti–BCL-XL payloads, though none has yet shown a clear clinical signal.1

Cooper also questioned how these drugs are dosed. "I think the maximum tolerated dose is probably not the right way to formulate and create these drugs," she said, pointing to dose splitting, ideal or adjusted body weight dosing, and multicleavable linkers as alternatives.1

Finally, she called for trials to collect longitudinal, prospective samples and to publish biomarker validation, including from negative studies. "It really is imperative for us to learn from the work that's ongoing, so that we can make the best decisions for our patients," Cooper concluded.1

References

  1. Cooper A. Novel constructs and targets for conjugated antibodies in NSCLC. Presented at: 44th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; November 11-13, 2026; New York, NY.
  2. Garassino MC, Ahn MJ, Schick M, et al. Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer. Nat Med. Published online November 11, 2026. doi:10.1038/s41591-026-04716-9
  3. Sands J, Lisberg A, Le X, et al. TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC. Presented at: European Lung Cancer Congress 2026; March 25-28, 2026; Copenhagen, Denmark. Abstract 42P.
  4. Fang W, Wu L, Meng X, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394(1):13-26. doi:10.1056/NEJMoa2512071
  5. Zhang L, Fang WF, Wu L, et al. Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study. Presented at: ESMO Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA67.
  6. Zhou F, Meng X, Ding Q, et al. Sacituzumab tirumotecan plus pembrolizumab in PD-L1-negative advanced NSCLC. N Engl J Med. Published online October 25, 2026. doi:10.1056/NEJMoa2611280
  7. Li Z, Wang Y, Sun Y, et al. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 2025;26(4):437-446. doi:10.1016/S1470-2045(25)00012-9
  8. Murciano-Goroff YR, et al. Telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with MET-amplified advanced solid tumors: results from a phase 1 study. Presented at: ESMO Congress 2025; October 17-21, 2025; Berlin, Germany. Abstract 918O.
  9. Sommerhalder D, Cho BC, Raimbourg J, et al. An overall survival analysis of telisotuzumab adizutecan (Temab-A) in non-squamous NSCLC from a phase 1 first-in-human study. Presented at: ESMO Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract 2658RO.
  10. Peters S, Piha-Paul SA, Sehgal K, et al. First-in-human, phase I study of sigvotatug vedotin, an integrin beta-6-directed antibody-drug conjugate: results from dose expansion in advanced non-small cell lung cancer. J Clin Oncol. 2026;44(17):1635-1645. doi:10.1200/JCO-25-02016
  11. Peters S, et al. Phase 3 study of sigvotatug vedotin versus docetaxel in previously treated nonsquamous non-small cell lung cancer. Presented at: ESMO Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA68.
  12. Hong S, Zhou T, Hou X, et al. Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China. Lancet. Published online October 26, 2026. doi:10.1016/S0140-6736(26)02026-X
  13. Sac-TMT plus pembrolizumab improves PFS in PD-L1–negative nonsquamous NSCLC. OncLive. October 28, 2026. Accessed November 17, 2026. https://www.onclive.com/view/sacituzumab-tirumotecan-plus-pembrolizumab-improves-pfs-in-pd-l1-negative-nonsquamous-nsclc
  14. Iza-bren improves PFS vs platinum chemo in EGFR-mutated NSCLC after third-generation TKI. OncLive. October 26, 2026. Accessed November 17, 2026. https://www.onclive.com/view/iza-bren-improves-pfs-vs-platinum-chemo-in-egfr-mutated-nsclc-after-third-generation-tki

Related to this article